Arch Biopartners Inc.
ARCH.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.44M | 1.57M | 1.02M | 1.11M | 1.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.44M | 1.57M | 1.02M | 1.11M | 1.36M |
| Cost of Revenue | 2.74M | 2.79M | 1.14M | 1.03M | 1.33M |
| Gross Profit | -1.30M | -1.22M | -121.40K | 78.00K | 26.80K |
| SG&A Expenses | 917.30K | 1.32M | 1.29M | 1.28M | 1.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.66M | 4.12M | 2.43M | 2.30M | 2.42M |
| Operating Income | -2.22M | -2.54M | -1.41M | -1.20M | -1.06M |
| Income Before Tax | -2.61M | -2.88M | -1.89M | -1.58M | -1.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.61 | -2.88 | -1.89 | -1.58 | -1.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.61M | -2.88M | -1.89M | -1.58M | -1.44M |
| EBIT | -2.22M | -2.54M | -1.41M | -1.20M | -1.06M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.04 | -0.05 | -0.03 | -0.03 | -0.02 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.02 | -0.02 | -0.01 |
| EPS Diluted | -0.04 | -0.05 | -0.03 | -0.03 | -0.02 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.02 | -0.02 | -0.01 |
| Average Basic Shares Outstanding | 251.22M | 248.75M | 250.57M | 250.28M | 249.59M |
| Average Diluted Shares Outstanding | 251.22M | 248.75M | 250.57M | 250.28M | 249.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
